The short interest data are out for the February 13 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Here are the four top biotech stocks to buy now according to Deutsche Bank. These leaders have established drugs, solid pipelines and, most importantly, earnings.
The short interest data are out for the January 30 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Logically, it seems that as they stock market zooms higher, insiders who want to buy stock would wait until a pullback to add new capital.
Gilead Sciences has become so large and accumulated enough capital that it has decided to begin paying a dividend, a move follows Amgen.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. For the majority of the selected stocks, short interest is down.
24/7 Wall St. has reviewed the short interest in the top biotech companies, without focusing on speculative companies.
A biosimilar application filing from Apotex has been accepted by the Food and Drug Administration for version of Amgen's Neulasta.
The short interest data are out for the November 28 settlement date, and 24/7 Wall St. has reviewed the top biotech companies.
ThinkstockThe short interest data are out for the November 14 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or…
ThinkstockAmgen Inc. (NASDAQ: AMGN) announced the termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer. This includes phase 3 RILOMET-1 and RILOMET-2 studies. The decision to discontinue was made…
Chris Lange 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies, such as Ebola-vaccine companies.
A new research note from Cowen focuses on health care companies that have released earnings and offer investors reasons to own the stocks.
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Wednesday, October 29, 2014.
Amgen reported better-than-expected third-quarter 2014 results after markets closed Monday afternoon.
Paul Ausick 
